A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Two Dose Levels of Privigen in Pediatric CIDP
-
Phoenix Children's Hospital, Phoenix, Arizona, United States, 85016
Children's Hospital of Los Angeles, Los Angeles, California, United States, 90027
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States, 52242-1009
Akron Children's Hospital, Akron, Ohio, United States, 44647
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104
Le Bonheur Children's Hospital, Memphis, Tennessee, United States, 38105
Neurology Rare Disease Center, Denton, Texas, United States, 76208
Children's Specialty Group, Norfolk, Virginia, United States, 23507
Seattle Children's Hospital, Seattle, Washington, United States, 98105
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
2 Years to 17 Years
ALL
No
CSL Behring,
Study Director, STUDY_DIRECTOR, CSL Behring
2029-12-20